Prelude Therapeutics Incorporated announced multiple clinical and preclinical posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, known as the Triple Meeting, from October 11 - 15, 2023 at the Hynes Convesntion Center in Boston, MA. The four Prelude poster presentations include data from two ongoing Phase 1 clinical trials for Prelude's CDK9 inhibitor, PRT2527, and CDK4/6 inhibitor, PRT3645, and two preclinical posters for SMARCA2 degrader compound, PRT3789.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.07 USD | +0.74% | +9.41% | -4.68% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.68% | 223M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- PRLD Stock
- News Prelude Therapeutics Incorporated
- Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference